Based on the key indicators related to BriaCell Therapeutics' liquidity, profitability, solvency, and operating efficiency, BriaCell Therapeutics Corp may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. At this time, BriaCell Therapeutics' Other Current Assets are fairly stable compared to the past year. Key indicators impacting BriaCell Therapeutics' financial strength include:
Investors should never underestimate BriaCell Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor BriaCell Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in BriaCell Therapeutics Corp.
Net Income
(4.53 Million)
BriaCell
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Invested Capital
Operating Cash Flow Per Share
Average Payables
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Average Inventory
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Tangible Asset Value
Ev To Operating Cash Flow
Pe Ratio
Ev To Free Cash Flow
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Roic
Payables Turnover
Roe
Return On Tangible Assets
Earnings Yield
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Days Of Inventory Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Fair Value
Return On Capital Employed
Return On Assets
Return On Equity
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Other Cashflows From Financing Activities
Other Non Cash Items
Sale Purchase Of Stock
Stock Based Compensation
Depreciation
Change To Account Receivables
Total Cashflows From Investing Activities
Other Cashflows From Investing Activities
Investments
Issuance Of Capital Stock
Change To Inventory
Total Assets
Total Current Liabilities
Total Stockholder Equity
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Other Stockholder Equity
Total Liab
Total Current Assets
Net Receivables
Other Current Liab
Property Plant And Equipment Net
Inventory
Other Current Assets
Accumulated Other Comprehensive Income
Short Term Investments
Intangible Assets
Current Deferred Revenue
Net Invested Capital
Net Working Capital
Short Long Term Debt Total
Long Term Debt
Short Long Term Debt
Capital Stock
Short Term Debt
Common Stock
Depreciation And Amortization
Interest Expense
Other Operating Expenses
Operating Income
Ebit
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Selling General Administrative
Research Development
Interest Income
Net Income Applicable To Common Shares
Net Interest Income
Net Income From Continuing Ops
Reconciled Depreciation
Gross Profit
Cost Of Revenue
Probability Of Bankruptcy
Understanding current and past BriaCell Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of BriaCell Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in BriaCell Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in BriaCell Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BriaCell Therapeutics Corp. Check BriaCell Therapeutics' Beneish M Score to see the likelihood of BriaCell Therapeutics' management manipulating its earnings.
BriaCell Therapeutics Stock Summary
BriaCell Therapeutics competes with Briacell Therapeutics. BriaCell Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
BriaCell Therapeutics Key Income Statement Accounts
The reason investors look at the income statement is to determine what BriaCell Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining BriaCell Therapeutics's current stock value. Our valuation model uses many indicators to compare BriaCell Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across BriaCell Therapeutics competition to find correlations between indicators driving BriaCell Therapeutics's intrinsic value. More Info.
BriaCell Therapeutics Corp is rated fifth in return on equity category among its peers. It also is rated fifth in return on asset category among its peers . At this time, BriaCell Therapeutics' Return On Equity is fairly stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value BriaCell Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
BriaCell Therapeutics Systematic Risk
BriaCell Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. BriaCell Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on BriaCell Therapeutics correlated with the market. If Beta is less than 0 BriaCell Therapeutics generally moves in the opposite direction as compared to the market. If BriaCell Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one BriaCell Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of BriaCell Therapeutics is generally in the same direction as the market. If Beta > 1 BriaCell Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in BriaCell Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various BriaCell Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of BriaCell Therapeutics growth as a starting point in their analysis.
BriaCell Therapeutics March 25, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of BriaCell Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of BriaCell Therapeutics Corp. We use our internally-developed statistical techniques to arrive at the intrinsic value of BriaCell Therapeutics Corp based on widely used predictive technical indicators. In general, we focus on analyzing BriaCell Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build BriaCell Therapeutics's daily price indicators and compare them against related drivers.
When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.